Overexpression and frequent FLT-3 mutations are associated with poor prognoses and AML pathogenicity and activate downstream signaling molecules, which leads to stimulation and survival of cancerous cells (Zhang and Broxmeyer, 1999; Hayakawa et al., 2000; Lin et al., 2012). This evidence concerns the gene FLT3 and acute myeloid leukemia.